Skip to content
Screener

PTC Therapeutics PTCT Net Change in Cash

Net Change in Cash at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
-$336.83M+60.9%
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
-$2.2B-1,432%
Capricor Therapeutics logo
Capricor TherapeuticsCAPR
-$182.43M-1,142%
ALN
Alnylam PharmaceuticalsALNY
$53.61M0.0%
Edgewise Therapeutics, Inc. logo
Edgewise Therapeutics, Inc.EWTX
-$27.94M-438%
Polaryx Therapeutics, Inc. logo
Polaryx Therapeutics, Inc.PLYX
13,050,000%-102,425,000pp

Other financials

Income statement

See full
Revenue$272.6M-76.8%
Operating income$45.0M-95.4%
Net income-$2.8M-100%
EPS (diluted)-$0.03-100%

Balance sheet

See full
Cash & equivalents$834.0M-43.7%
Total debt$395.1M+0.1%
Total equity-$180.5M+2.9%
Total assets$2.9B+8.0%

Cash flow

See full
Operating cash flow-$59.0M-107%
CapEx$1.2M-30.6%
Free cash flow-$60.2M-107%

Valuation

See full
Market cap$5.91B+45.3%
Enterprise value$5.47B+58.8%
P/E7.3×
P/S7.2×+4.8×

Profitability

See full
Gross margin96%
Operating margin1.6%-38.7pp
Net margin42.3%+27.4pp
FCF margin39.1%+32.8pp

Returns & leverage

See full
Return on equity-216.7%
Debt / equity372.3×
Current ratio2.4×-1.5×

Where this comes from

Reported directly by PTC Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The source filing: PTC Therapeutics’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:32 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001070081-26-000012
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Payments on contingent consideration obligation(6,341)
Net cash provided by financing activities$6,403$9,410
Effect of exchange rate changes on cash(1,524)5,393
Net (decrease) increase in cash and cash equivalents(147,899)700,546
Cash and cash equivalents, and restricted cash beginning of period998,334795,316
Cash and cash equivalents, and restricted cash end of period$850,435$1,495,862
Supplemental disclosure of cash information
Cash paid for interest$2,156$2,156

Item 1. Financial Statements (unaudited)

FAQ

What is PTC Therapeutics's net change in cash?
PTC Therapeutics (PTCT) reported net change in cash of -$147.9M in Q1 2026.
How has PTC Therapeutics's net change in cash changed year-over-year?
PTC Therapeutics's net change in cash decreased by 121.1% year-over-year, from $700.55M to -$147.9M.
What is the long-term trend for PTC Therapeutics's net change in cash?
Over 2 years (2022 to 2024), PTC Therapeutics's net change in cash has grown at a 36.9% compound annual growth rate (CAGR), from $98.71M to $185.03M.
What does net change in cash mean?
Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.

Ask your AI about PTC Therapeutics's net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude